Show simple item record

dc.contributor.authorEstil, Svein
dc.contributor.authorSteinarsson, AEgir Þór
dc.contributor.authorEinarsson, Stefan
dc.contributor.authorAspelund, Thor
dc.contributor.authorStefánsson, Einar
dc.date.accessioned2020-05-06T09:52:33Z
dc.date.available2020-05-06T09:52:33Z
dc.date.issued2020-03-25
dc.date.submitted2020-05
dc.identifier.citationEstil S, Steinarsson AÞ, Einarsson S, Aspelund T, Stefánsson E. Diabetic eye screening with variable screening intervals based on individual risk factors is safe and effective in ophthalmic practice [published online ahead of print, 2020 Mar 25]. Acta Ophthalmol. 2020;10.1111/aos.14425. doi:10.1111/aos.14425en_US
dc.identifier.pmid32216034
dc.identifier.doi10.1111/aos.14425
dc.identifier.urihttp://hdl.handle.net/2336/621372
dc.description.abstractPurpose: To test in a 'real world' diabetic eye-screening programme, a computer-based personal risk evaluation for progression to sight-threatening diabetic retinopathy. Screening intervals were individualized, and clinical outcomes, safety and cost-effectiveness documented. Methods: The RETINARISK algorithm was used in an ophthalmology clinic in Norway. The diabetes cohort was divided on voluntary basis into two groups: one with variable screening intervals based on their personal risk profile and the other group with conventional fixed interval diabetic eye screening. Compliance, clinical outcomes, safety and health economics were evaluated. A total of 843 diabetic patients participated in the program 2014-2019. A total of 63 had type 1 and 780 type 2 diabetes. A total of 671 patients had no diabetic retinopathy at baseline and 171 had retinopathy. Results: A total of 444 (53%) diabetic patients were included in the personal risk profile program and 399 in the fixed interval group. The RETINARISK algorithm calculated 563 screening intervals for the variable interval group, which was 23 ± 16 months (mean ± SD), compared to 14 ± 5 months for the group with fixed screening intervals. Due to selection bias, the two groups could not be directly compared. We did not experience any delay in detecting diabetic retinal changes when using the personal risk profile program. Conclusion: The RETINARISK algorithm was safe and effective in a diabetic screening program in an ophthalmology clinic over 5 years. The use of the program reduces the mean frequency of screening visits and liberates valuable time in ophthalmic practice to be used on high-risk diabetic patients or other patient groups.en_US
dc.description.sponsorshipOphthalmologist Otto Johansen Foundation Norwegian Ophthalmological Society Research Foundationen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.urlhttps://onlinelibrary.wiley.com/doi/full/10.1111/aos.14425en_US
dc.rights© 2020 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
dc.subjectblindnessen_US
dc.subjectdiabetic retinopathyen_US
dc.subjecthealth careen_US
dc.subjecthealth economicsen_US
dc.subjectinformation technologyen_US
dc.subjectrisken_US
dc.subjectrisk factorsen_US
dc.subjectrisk profileen_US
dc.subjectscreeningen_US
dc.subjectSykursýkien_US
dc.subjectAugnsjúkdómaren_US
dc.subjectSjúkdómsgreiningen_US
dc.subject.meshDiabetic Retinopathyen_US
dc.subject.meshDiabetes Mellitusen_US
dc.subject.meshDiagnostic Techniques and Proceduresen_US
dc.subject.meshEye Diseasesen_US
dc.titleDiabetic eye screening with variable screening intervals based on individual risk factors is safe and effective in ophthalmic practice.en_US
dc.typeArticleen_US
dc.identifier.eissn1755-3768
dc.contributor.department1Robrygga Eye, Namsos Medical Center, Namsos, Norway. 2Risk ehf, Reykjavík, Iceland. 3Landspitali University Hospital, University of Iceland, Reykjavik, Iceland.en_US
dc.identifier.journalActa ophthalmologicaen_US
dc.rights.accessNational Consortium - Landsaðganguren_US
dc.departmentcodeOPH12
dc.source.journaltitleActa ophthalmologica
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record